Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAA

▴ Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAA
MarzAA for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors

Catalyst Biosciences, Inc.announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this month.

The Fast Track program is designed to facilitate and expedite the development and review of drug candidates that have demonstrated the potential to address an unmet medical need in treating serious diseases or conditions. A drug candidate with Fast Track designation is eligible for greater access to the FDA as well as a priority review and rolling review of the marketing application.

“We believe the FDA Fast Track Designation validates MarzAA’s potential to improve patient care. As the only SQ delivered therapy in development for on-demand treatment of bleeding events, MarzAA is uniquely positioned to become an important addition to the treatment landscape,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.

The Phase 3 CRIMSON 1 study is an open-label, global, multi-center, randomized, cross-over study, designed to evaluate the safety and efficacy of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia A or B with inhibitors, compared to the Standard of Care. The study will enroll approximately 60 subjects to treat 244 eligible bleeding episodes with each treatment. The primary endpoint for the trial is the percentage of treated bleeds resulting in effective hemostasis at the 24-hour timepoint. The objective of the trial is to demonstrate non-inferiority of MarzAA compared with Standard of Care.

Tags : #CatalystBiosciences #FDAApprovalDec4 #Marzaa #Hemophilia #CrimsonTrial

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

India Joins International Medical Device Regulators Forum: A Leap Toward Global Health CollaborationOctober 05, 2024
The Science of Overeating: Why You Can’t Stop at Just One BiteOctober 05, 2024
The Toxic Truth: How Alcohol Fuels Six Deadly CancersOctober 05, 2024
Lenacapavir: India’s Pharmaceutical Giants to Produce a Twice-a-Year Pill Poised to Rewrite HIV PreventionOctober 04, 2024
Can Ending Smoking by 2050 Really Save 1.2 Million Lives? New Lancet Study RevealsOctober 04, 2024
Colon Cancer Crisis: Why It’s Attacking Younger GenerationsOctober 04, 2024
Eye Health Program for Low-Income Residents Launched in Hingoli, MaharashtraOctober 04, 2024
Are we on the path to end AIDS by 2030?October 03, 2024
TTK Prestige Announces Shubhutsav- A Special Festive Offer, Elevating Home CookingOctober 03, 2024
Tata Soulfull Launches Tata Soulfull Corn Flakes+, With the Goodness of Millets in Every Flake October 03, 2024
The Bitter Truth Behind Sweet Treats: Hidden Cancer Risks in Your Favorite CakesOctober 03, 2024
Ageing Faster Than You Think? Discover How a Simple Cheek Swab Could Save Your LifeOctober 03, 2024
The University of Tasmania invites international student applications for their Tasmanian International ScholarshipOctober 03, 2024
A New Hope for Type 1 Diabetes: Tackling Blood Sugar Drops with Somatostatin BlockersOctober 03, 2024
Prostate Cancer Strikes Young: The Alarming Rise of Aggressive Cases in Men Under 50October 03, 2024
Fleetguard Filters Private Limited (FFPL) Wins Prestigious ‘Iconic Brands of India 2024’ at the This recognition adds to Fleetguard's growing list of accolades, further establishing its position as a leader in the automotive industry. The company remains dedicated to advancing innovation and providing solutions that consistently meet the changing needs of its customers.October 03, 2024
Marico’s Saffola Honey and Pankaj Tripathi Uncover the Secret of Shuddha Honey in its latest TVCOctober 01, 2024
Mr. Piush Srivastava, Head of Marketing and Corporate Communications of Fleetguard Filters Pvt. Ltd, Awarded 'Marketing Maverick' by Dun & Bradstreet October 01, 2024
Chikungunya Strikes Back: The Forgotten Virus Making a Deadly ComebackOctober 01, 2024
The Hidden Cancer Risk in Your Morning Routine: How Poor Oral Hygiene May Be Endangering Your HealthOctober 01, 2024